Seely Lynn

Seely Lynn is listed in filings as President and CEO at Lyell Immunopharma, Inc.. This profile follows SEC Form 4 activity through Feb 12, 2026, including sale activity and purchase activity. Recent filings connect the profile to Lyell Immunopharma, Inc. (LYEL) and Blueprint Medicines Corporation (BPMC). The current snapshot covers public activity from Feb 26, 2025 to Feb 12, 2026. Reported amounts are shown as $174.4K to $10.1K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.